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Abstract
The purpose of the European Stroke Organisation–Karolinska Stroke Update Conference is to provide updates on
recent stroke therapy research and to give an opportunity for the participants to discuss how these results may be
implemented into clinical routine. The meeting started 22 years ago as Karolinska Stroke Update, but since 2014 it is
a joint conference with European Stroke Organisation. Importantly, it provides a platform for discussion on the
European Stroke Organisation guidelines process and on recommendations to the European Stroke Organisation
guidelines committee on specific topics. By this, it adds a direct influence from stroke professionals otherwise not
involved in committees and work groups on the guideline procedure. The discussions at the conference may also
inspire new guidelines when motivated. The topics raised at the meeting are selected by the scientific programme
committee mainly based on recent important scientific publications. This year’s European Stroke Organisation–
Karolinska Stroke Update Meeting was held in Stockholm on 11–13 November 2018. There were 11 scientific
sessions discussed in the meeting including two short sessions. Each session except the short sessions produced
a consensus statement (Full version with background, issues, conclusions and references are published as web-material and
at www.eso-karolinska.org and http://eso-stroke.org) and recommendations which were prepared by a writing
committee consisting of session chair(s), scientific secretary and speakers. These statements were presented to
the 250 participants of the meeting. In the open meeting, general participants commented on the consensus state-
ment and recommendations and the final document were adjusted based on the discussion from the general
participants Recommendations (grade of evidence) were graded according to the 1998 Karolinska Stroke Update
meeting with regard to the strength of evidence. Grade A Evidence: Strong support from randomised controlled
trials and statistical reviews (at least one randomised controlled trial plus one statistical review). Grade B Evidence:
Support from randomised controlled trials and statistical reviews (one randomised controlled trial or one statistical
review). Grade C Evidence: No reasonable support from randomised controlled trials, recommendations based on
small randomised and/or non-randomised controlled trials evidence.
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Speakers: Heinrich Audebert (Berlin), Urs Fischer
(Bern), Guillaume Turc (Paris).
What is proven (glyceryl trinitrate, oxygen,
preconditioning, mobile stroke units)?
Q1: For acute ischaemic stroke (AIS) patients: Does
prehospital glyceryl trinitrate application improve
outcome?
Recommendation: There is currently not sufficient
evidence to recommend the application of GTN in
the prehospital field (Grade C).
Q2: Does prehospital oxygen supply improve outcome in
ischaemic stroke patients? Recommendation: There is no
evidence available from prehospital trials. Results from
one meta-analysis of trials performed during in-hospital
care suggest that oxygen treatment is harmful do not
support the use of oxygen supply in non-hypoxemic
patients in prehospital stroke management (Grade C).
Q3: Does preconditioning lead to better outcomes in
ischaemic or haemorrhagic stroke?
Recommendation: There is currently not sufficient
evidence to recommend remote ischaemic precondi-
tioning in prehospital stroke care (Grade C).
Q4: For AIS patients: Do mobile stroke units (MSU)
reduce time to treatment?
Q5: For AIS patients: Do mobile stroke units
improve outcome?
Recommendation:Mobile stroke units can be used to
effectively reduce time to intravenous thrombolysis
that is related to better outcome. However, there is
currently not sufficient evidence whether and to what
extent mobile stroke units improve outcome of AIS
patients. Further evaluation is needed with regard to
adaptation of the MSU concept to different health care
settings. Because of costs and resource use of mobile
stroke units, their routine use can currently not be rec-
ommended (Grade C).
Prehospital identification of candidates for
mechanical thrombectomy
Q1: Can clinical scores reliably predict a large artery
occlusion (LAO) in unselected patients with a suspected
AIS in the prehospital setting?
Q2: Different clinical scores have been designed to
predict LAO in AIS patients: are all scores equally pre-
dictive or are several scores superior to others?
Q3: Should cut-off levels be recommended to
triage patients?
Recommendation: Prehospital scales provide only a
gross estimate of the presence or absence of an LAO.
They are inadequate to exclude LAO with certainty
and many triage positive patients may have no LAO
(Grade C).
Because none of the currently published scales has
both high sensitivity and specificity and there is no evi-
dence for the superiority of any prediction instrument,
we cannot recommend the prioritization of one partic-
ular scale over the others. Further efforts are needed to
prospectively test and validate the different scores in
unselected patients with suspected stroke in the preho-
spital setting by paramedics (Grade C).
Recommended cut-off level of any triage score
depends on the geographic situation and hospital infra-
structure. In the proximity of Mechanical thrombec-
tomy (MT) capable stroke centres, we suggest aiming
for a highly sensitive triage tool in order to identify
most patients with LAO. In areas with long distances
to the next MT stroke centre, a high specificity to detect
LAO is reasonable (Grade C).
Drip-and-ship versus mothership for thrombectomy
Q1: What referral system works best for endovascular
treatment?
Recommendation: As there is lack of randomized evi-
dence for superiority of one organizational model, the
choice of model should depend on local and regional
service organization and patient characteristics
(Grade C).
For patients without identified contraindication to
Intravenous thrombolysis (IVT), if estimated transpor-
tation time to a comprehensive stroke centre is consid-
erably longer than transportation to the nearest
primary stroke centre (approximately more than 30–
45 min), the drip-and-ship model should be considered
(Grade C).
Conversely, if the difference in travel time between
the nearest primary stroke centre and the nearest com-
prehensive stroke centre is below 30–45 min, or if con-
traindications to IVT are suspected in the field (i.e.
recent surgery, oral anticoagulation. . .), direct trans-
portation to the comprehensive stroke centre should
be considered if LAO is deemed clinically plausible
(Grade C).
We recommend that patients in late time windows
(beyond 6h) or with unknown time of symptom onset
(wake-up stroke, unwitnessed stroke) have rapid access
to advanced imaging (Grade A).
In case of admission to a primary stroke centre,
evaluation and treatment for patients with suspected
ischaemic stroke must be expeditious but should
include brain and intracranial arterial imaging to
ensure rapid identification of candidates for secondary
transfer to a comprehensive stroke centre. In case of
intravenous thrombolysis, the door-to-needle time
should be kept as low as possible, ideally below
30 min (Grade C).
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The first picture-to-puncture time and the door-in-
door-out time in drip-and-ship patients should be as
low as possible, ideally less than 90 min and 60 min
respectively (Grade C).
Session 2: Acute management of
subarachnoid haemorrhage (SAH)/
intracerebral haemorrhage (ICH)
Chair: Charlotte Cordonnier (Lille), Hanne
Christensen (Copenhagen). Secretary: Erik
Lundstr€om (Stockholm). Speakers: Gabriel J. E.
Rinkel (Utrech), Charlotte Cordonnier (Lille), Hanne
Christensen (Copenhagen).
Q1: SAH – Which diagnostic test and when?
Recommendation:
1. In patients suspected to have a subarachnoid hae-
morrhage from a ruptured aneurysm, CT scanning of
the brain is the first line examination.
2. If CT performed within 6 h after the onset of
headache and is read negative by a radiologist experi-
enced in reading brain CT, Cerebrospinal fluid (CSF)
examination is not indicated. If CT is performed more
than 6 h after onset and negative, lumbar puncture
should be performed more than 12 h after headache
onset, and CSF examined for bilirubin (Grade B).
3. In patients with SAH, computed tomography
angiography (CTA) is a sensible first-line examination
to detect an aneurysm (Grade B). According to the
local health care system it can be performed in either
the local hospital or the neuro-intervention centre.
4. In patients with a perimesencephalic pattern of
haemorrhage on CT within three days and a negative
CTA, no further imaging is needed (Grade B).
5. In patients with an aneurysmal pattern of hae-
morrhage and a negative CTA, repeated vascular imag-
ing (CTA or Digital subtraction angiography (DSA))
should be performed within one or two days. If this
second imaging is again negative, a third imaging is
indicated in the second week after SAH, and if negative
again a fourth after three months (Grade C).
Q2: Intracerebral haemorrhage (ICH) – Which diag-
nostic test and when?
Recommendation:
1. ICH is a heterogeneous disease and clinicians
should identify the underlying cause of the bleeding
(Grade C).
2. At admission: CT angiography spot sign predicts
haematoma growth but whether treatments tailored to
this information may improve outcome remains uncer-
tain (Grade C).
3. At admission: vessel imaging should be performed
to detect an underlying cause: CTA/Computed tomog-
raphy venography (CTV) or Magnetic resonance
angiography (MRA)/Magnetic resonance venography
(MRV) in patients in whom early intervention is con-
sidered (Grade C).
4. In patients without identified vascular malforma-
tions, brain parenchyma should be explored to see
markers of the disease, ideally with MRI (Grade C).
5. In the absence of markers of deep perforating
vasculopathy or cerebral amyloid angiopathy (CAA),
even in CTA negative patients: conventional DSA
should be performed if the benefit/risk ratio of the
DSA is acceptable. Conventional DSA should be per-
formed between two and six months after ICH
(Grade C).
Q3: TICH-2 (Tranexamic acid for hyperacute
primary intracerebral haemorrhage trial): what lessons
have we learned?
Recommendation:
1. Inclusion window in acute ICH trials aiming at
preventing haematoma expansion should be as short as
possible and no longer than 4.5 h from ictus (Grade C).
2. As part of future trial protocols, BP should be
controlled (140 mmHg systolic) (Grade C).
3. Future studies in ICH should include large
number of patients, have no upper age limit and
include proportional number of women (Grade C).
Session 3: Blood pressure (BP) and
glucose control after stroke
Chair: Simona Sacco (L’Alquila), Else Charlotte
Sandset (Oslo). Secretary: Marius Matusevicius
(Stockholm). Speakers: Georgios Tsivgoulis (Athens),
Thorsten Steiner (Heidelberg), Else Charlotte
Sandset (Oslo).
Q1: Does blood glucose influence outcome in acute
ischaemic or haemorrhagic stroke, and how should it
be managed?
Recommendation: Hypo- and hyperglycaemia in the
acute phase of both ischaemic and haemorrhagic stroke
is associated with adverse outcomes (Grade C).
Tight glycaemic control with intravenous insulin
does not improve stroke outcomes and is associated
with increased risk of hypoglycaemia (Grade A).
Hyperglycaemia in acute (<48 h) stroke patients
may be treated as any other hospitalised patient with
a therapeutic target of 140–180 mg/dL (7.8–10mmol/L)
using intravenous insulin therapy. Subcutaneous
sliding-scale insulin should be avoided (Grade C).
Hyperglycaemia is associated with adverse outcomes
in AIS patients treated with IVT and/or MT and
should be corrected with a therapeutic target
<140 mg/dL (7.8 mmol/L) before and after treatment
with acute reperfusion therapies (Grade C).
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Hypoglycaemia (<67 mg/dL or 3.7 mmol/L) in AIS
or acute ICH should be actively treated (Grade C).
Q2: Should BP be lowered in the chain of treatment in
patients with AIS and high BP?
Recommendation: In patients with AIS who do not
receive recanalization therapy, BP should not be low-
ered unless, very high (>220/120 mmHg). Treatment
should be individualized and tailored according to pre-
vious hypertension and other comorbidities (Grade B).
In AIS patients treated with IVT, we suggest to keep
the BP thresholds of the clinical trials: 185/110
mmHg before treatment, and of 180/105 mmHg for
the first 24 h after treatment (Grade C).
In patients treated with endovascular recanalization,
we suggest to keep BP pre-, intra- and post-procedural
185/110 mmHg. However, we suggest to pursue
recanalization therapy irrespective of BP in patients
with large vessel occlusions and major neurological def-
icits (Grade C).
Q3: Should hypertension be induced in patients with
ischaemic stroke?
Recommendation: In patients with large vessel occlu-
sion, fluctuating symptoms, and low systolic BP who
are ineligible for recanalization therapy, it is reasonable
to consider systolic BP elevation to prevent early neu-
rological deterioration (Grade C).
Q4: What is the optimal BP in acute ICH?
Recommendation: In patients with acute ICH we rec-
ommend to lower systolic BP below 140 mmHg but to
keep it above 110 mmHg and to avoid Systolic blood
pressure (SBP) reduction of more than 90 mmHg to
prevent acute kidney injury (Grade B).
In patient with acute ICH, we recommend to lower
BP as soon and fast as possible: The optimal onset to
treatment (OTT) time to impact on clinical outcome is
probably as short as 2.5 h (Grade C).
Still, after this period, BP should be kept <140
mmHg, because haematoma expansion does occur
even after this time (Grade C).
Q5: BP lowering in acute ICH: What is the influence
of time, haematoma volume, choice of agent and previous
hypertension?
Recommendation: In patients with acute ICH and
previous hypertension recommend to lower BP as
soon and fast as possible (Grade C).
The optimal OTT to impact on clinical outcome
may be 2.5 h, but BP should be kept <140 mmHg,
because the risk of haematoma expansion exists even
after this time (Grade C).
We recommend the use of short-acting intravenous
drugs to lower SBP in the acute phase of ICH
(Grade C).
In patients with acute ICH and small bleeding vol-
umes we recommend to lower BP as soon and fast
as possible to an SBP below 140 mmHg and above
110 mmHg but to avoid SBP reduction of more
than 90 mmHg to prevent acute kidney injury
(Grade C).
Session 4: Title: Update on work-up and
secondary prevention issues 1
Chair: Andreas Charidimou (Boston), George Ntaios
(Larissa). Secretary: Tiago Moreira (Stockholm).
Speakers: George Ntaios (Larissa), Haralampos
Milionis (Ioannina), Marta Rubiera (Barcelona),
Robert G. Hart (Hamilton).
Q1: What is good clinical practice in work up for
suspected cardio-embolic cases? Echo and monitoring in
all patients?
Recommendation:
1. A good medical history, physical examination, lab-
oratory testing, a 24-h 12-lead electrocardiogram
(ECG) and transthoracic echocardiogram (TTE)
are the mainstays of cardioembolic source detection
(Grade A).
2. Screening of patent foramen ovale (PFO) with
bubble test-transcranial Doppler or transoesopha-
geal echocardiogram (TEE) is recommended in
patients with embolic stroke of undetermined aetiol-
ogy despite recommended diagnostic work up, who
would be eligible for PFO closure (Grade A).
3. Screening of aortic arch atheroma (AAA) with CTA
or TTE is recommended in embolic strokes of unde-
termined source (ESUS); however, TEE is still the
gold standard for AAA evaluation (Grade C).
4. Detection of some minor structural abnormalities on
TEE has uncertain therapeutic implications
(Grade C).
5. Continuous monitoring of heart rhythm up to 30
days is reasonable in patients with embolic stroke
of undetermined aetiology despite recommended
diagnostic work up to increase covert atrial fibrilla-
tion (AF) detection (Grade A). However, it remains
to be firmly established that the increased detection
of brief episodes of AF will lead to a reduction in
stroke recurrence after adequate treatment
(Grade C).
6. Covert AF can be associated with increased brain
natriuretic peptide (BNP) and N-terminal-pro-BNP
in laboratory tests; atrial ectopic activity, subclinical
atrial tachyarrhythmias in Holter–ECG; left
atrium enlargement, left ventricular diastolic dys-
function, spontaneous left atrium or left atrial
apex (LAA) echo-contrast and low LAA emptying
velocities in TTE/TEE. These findings should
encourage long-term monitoring in ESUS patients
(Grade C).
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Q2: How to choose secondary prevention in ESUS?
Recommendation:
1. The best current secondary prevention in ESUS
patients is antiplatelet treatment (Grade A) (pending
publication of the RE-SPECT ESUS trial).
2. ESUS patients are relatively young and have 5%
yearly stroke recurrence despite guideline-
recommended therapy and thus represent a substan-
tial unmet need in secondary stroke prevention
(Grade C).
3. Subgroups of ESUS patients who may benefit from
anticoagulation have not yet been validated by clin-
ical trials (Grade C).
Q3: What secondary prevention in multiple stroke
aetiologies?
Recommendation:
1. Patients with multiple stroke aetiologies represent a
significant proportion of the embolic stroke popula-
tion. The optimal strategy for secondary prevention
in these patients is uncertain (Grade C).
Q4: Lipids and stroke: Statins, PCSK9 inhibitors, and
Low-density lipoprotein cholesterol (LDL-C) levels; and
whom not to treat?
Recommendation:
1. We recommend that statins be used as a part of
standard secondary prophylactic treatment after an
ischaemic stroke or a transient ischaemic attack
(TIA). Most benefit was observed with atorvastatin
80mg (Grade A). Aggressive Intensive lipid lowering
therapy with statins plus/minus ezetimibe reduces
the risk of stroke in stroke survivors in a LDL-C
dependent manner (Grade A).
2. PCSK9 inhibitors represent a therapeutic option on
top of statin plus/minus ezetimibe therapy to achieve
very low LDL cholesterol target levels (Grade B).
The addition of evolocumab was shown to reduce
the risk of ischaemic stroke in patients with stabi-
lized cardiovascular disease and the addition of alir-
ocumab reduced the risk of ischaemic stroke in
patients with acute coronary syndrome (Grade A).
Evolocumab has been reported to reduce atheroscle-
rotic vascular disease (AVD) risk in patients with a
previous history of stroke (Grade B).
3. The use of statins in secondary prevention of ischae-
mic stroke caused by less frequent non-
atherosclerotic aetiologies such as arterial dissection
and PFO requires further investigations.
4. Lipid lowering treatment with statins in combina-
tion with lifestyle changes is recommended is the
mainstay for primary prevention of ischaemic
stroke in patients who have high 10-year risk for
cardiovascular events. The patients with diabetes
and patients with multiple risk factors appear to
benefit the most (Grade A). The drug-class and the
intensity of the lipid-lowering treatment as well as
the treatment goals are thus dependent on patient
characteristics (Grade A).
5. Statins should be used with caution in patients with
previous spontaneous ICH (Grade C). Using high-
dose statin regimens in patients with ICH should be
decided on an individual patient basis. In a sub-
group of patients with CAA-related lobar ICH,
statin use should probably be reserved for compel-
ling indications (Grade C).
6. There is no evidence from Randomized controlled
trials (RCTs) to support the routine use of statins in
the acute phase of stroke (first two weeks). However,
observational studies do not show an increase in
symptomatic ICH in patients previously treated
with statins or to whom statin was given within
three days after stroke. Statin treatment is thus rec-
ommended to start before discharge from hospital
after an AIS or at least during follow-up (Grade C).
Session 5: Update on secondary
prevention issues 2
Chair: Danilo Toni (Rome) and Christian Pristipino
(Rome). Secretary: Maria Lantz (Stockholm).
Speakers: Christina Sj€ostrand (Stockholm),
Christian Pristipino (Rome), Grethe Andersen
(Aarhus) and Peter Schellinger (Minden).
Q1: Does percutaneous closure of PFO versus anti-
platelet therapy reduce the risk of stroke recurrence?
Recommendation: In patients aged 18–60 years old
with cryptogenic stroke/TIA and with high risk PFO
features (moderate or severe shunt, atrial septal aneu-
rysm (ASA), atrial septal hypermobility) we recom-
mend percutaneous closure plus medical therapy
instead of antiplatelet therapy alone (Grade A).
In patients between 60 and 65 years, percutaneous
closure plus medical therapy instead of antiplatelet
therapy alone can be offered (Grade B).
Percutaneous closure plus medical therapy can be
considered in place of antiplatelet therapy alone also
for patients aged <18 and >65 years old on an indi-
vidual basis (Grade C).
Q2: Does percutaneous closure of PFO versus oral
anticoagulants reduce the risk of stroke recurrence?
Recommendation: Based on the few available data,
percutaneous closure and Oral anticoagulation (OAC)
therapy seem to perform equally (Grade C). Therefore,
while waiting for further evidence and based on the
superiority of percutaneous closure over medical
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therapy as a whole, patient engagement in the choice
becomes pivotal.
Adequately dimensioned randomised clinical trials
addressing the comparison between percutaneous clo-
sure plus medical therapy versus OAC (vitamin-K
antagonists or direct OAC) in carefully characterised
patients with cryptogenic cerebrovascular accident and
different risk characteristics, should be performed.
Q3: Does oral anticoagulant therapy versus antiplate-
let therapy reduce the risk of stroke recurrence?
Recommendation: In patients in whom a medical
therapy only is chosen, we recommend to choose the
specific drugs weighing the individual risk of bleeding
against the risk of PFO-related stroke recurrence, in
close connection with the patient. Long-term OAC
with vitamin K antagonists (VKAs) may be preferred
if: (a) the patient has a low haemorrhagic risk, (b) a
probable good therapeutic compliance is foreseen
and (c) a proper anticoagulant monitoring can be guar-
anteed (Grade B).
We recommend to perform adequately dimensioned
head-to-head randomised clinical trials addressing the
comparison between single antiplatelet drugs versus
OAC (vitamin-K antagonists or Direct oral anticoagu-
lants (DOAC)) in patients in which percutaneous clo-
sure has been excluded.
Q4: In patients with non-valvular AF and previous
ischaemic stroke or TIA, does left atrial appendage clo-
sure reduce risk of recurrent stroke or thromboembolism
compared to oral anticoagulant treatment?
Q5: In patients with non-valvular AF and previous
ischaemic stroke or TIA, does left atrial appendage clo-
sure lead to lower risk of serious adverse events com-
pared to oral anticoagulant treatment?
Q6: In patients with non-valvular AF and previous
ischaemic stroke or TIA submitted to left atrial append-
age closure, does antiplatelet treatment reduce risk of
thrombus formation on the device compared to oral anti-
coagulant treatment?
Consensus statement: The presently available data
from randomized controlled trials do not allow to pro-
vide a recommendation on LAA closure in patients
with non-valvular AF and previous ischaemic stroke
or TIA, as an alternative to oral anticoagulant therapy.
Recommendation: Patients with non-valvular AF
and previous ischaemic stroke or TIA with high risk
of bleeding or other contraindications to OAC should
be included in randomised controlled trials if possible
(Grade C).
Waiting for RCTs, LAA closure might be consid-
ered in selected patients with absolute contraindica-
tions to OAC/DOAC (Grade C).
LAA closure is safer than OAC in terms of risk of
bleeding in the long term, but is less safe in term of
short-term complications.
In case of LAA closure in patients at very high risk
of intra- and/or extra-cranial bleeding, post-procedural
aspirin as single antithrombotic therapy for at least six
months or lifelong may be used (Grade C).
Session 6: Clinical stroke trials
Chair: Hanne Christensen (Copenhagen) and Martin
K€ohrmann (Essen). Secretary: Konstantinos Kostulas
(Stockholm). Speakers: Martin K€ohrmann (Essen),
Georgios Tsivgoulis (Athens).
Q1: How do we increase the generalisability of future
stroke trials especially as to women and the old?
Consensus statement: More evidence is urgently
required regarding the effects of treatment interven-
tions (benefit and harm) in especially elderly women
with stroke. Trial designs tend not to match the epide-
miology of stroke leading to reduced external validity
and lack of generalisability to a significant part of the
stroke population.
Recommendation:
1. Effects of age and sex should be reported in all trials
(Grade A).
2. Enrolment age limits for randomized controlled
trials should be avoided, and enrolment should
mirror the sex distribution of the disease being inves-
tigated (Grade B)
3. Exclusion criteria for comorbidity and handicap
should be designed to exclude only more extreme
presentations or specific safety issues (Grade B).
Q2: Clinical end-point trials for prolonged cardiac
monitoring in stroke.
Consensus statement: More evidence from adequate-
ly powered randomized clinical trials with sufficient
follow-up time is needed to further investigate the
impact of Prolonged cardiac monitoring (PCM) on sec-
ondary stroke prevention and other clinical endpoints.
Recommendation:
1. PCM can identify a significant proportion of
Ischemic stroke (IS) patients with occult PAF, not
detected by conventional cardiac monitoring
(Grade A).
2. PCM may have a substantial impact in secondary
stroke prevention, through the identification and
prompt anticoagulant initiation in IS patients with
occult PAF (Grade C).
3. Selection of patients based on clinical and echocar-
diographic parameters may further enhance the
diagnostic utility of PCM, and further increase its
cost-effectiveness (Grade C).
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Session 8: Post-stroke early mobilisation
Chair: Niaz Ahmed (Stockholm). Speaker: Katharina
Sunnerhagen (G€oteborg)
Q1: Should we avoid early mobilization after AVERT
(A very early rehabilitation trial)?
Recommendations:
The evidence point to that early mobilization is safe in
stroke patients but should not be too intense (Grade B).
A progressive adaptation to activities of daily living,
such as going to the toilet with assistance (if needed) or
sitting in a chair to eat is fine (Grade A).
Patient should be clinically observed and monitored
closely and in case they present symptoms noted
(Grade C).
Early mobilization after a stroke should be adapted
to patient’s clinical and neurological situation
(Grade C).
Session 9: Oral anticoagulation and
reversal agents after stroke
Chair: Joji Kuramatsu (Erlangen) and Thorsten Steiner
(Frankfurt/Main). Secretary: Boris Keselman
(Stockholm). Speakers: Andreas Charidimou
(Boston), Eleni Korompoki (Athens/London) and Jan
Purrucker (Heidelberg).
Q1: In patients with ICH and oral anticoagulation,
how is optimal reversal under VKAs or novel oral anti-
coagulants (NOAC) achieved to improve outcomes (mor-
tality and functional outcome); specifically, in ICH to
reduce haematoma growth?
Recommendation:
In acute ICH, reversal of anticoagulation should be
started as soon as possible after diagnosis of ICH
(Grade B: VKA; Grade C: NOAC).
In VKA–ICH, optimal reversal is achieved by imme-
diate application of four-factor Prothrombine complex
concentrate (PCC) (30 IU/kg):
• If INR  2.0 (Grade B).
• If INR  1.3 but <2.0, a dose reduction to 10–25
IU/kg (dose depending on the INR) can be consid-
ered. (Grade C).
In VKA–ICH, the target INR after reversal is <1.3
(Grade B).
In VKA–ICH, INR should be monitored serially to
trigger possible rescue therapy (repeated PCC applica-
tion) (Grade C).
In VKA–ICH, all reversal treatments should be
accompanied by Vitamin K administration (10 mg, i.
v.; repeated doses depending on results of sequential
INR measurements) (Grade C).
In NOAC–ICH, reversal treatment should not be
delayed by waiting for results of coagulation test
(Grade C).
In dabigatran–ICH, reversal treatment should be
carried out by immediate application of idarucizumab
(Bolus 2 2.5 g intravenously) (Grade C).
In factor Xa inhibitor–ICH, reversal treatment
should be carried out by immediate application of
andexanet alfa if marketed or within a study (Grade C).
In factor Xa inhibitors–ICH (if andexanet is
unavailable), reversal treatment should be carried out
by immediate application of high-dose 4-factor PCC
(50 IU/kg) (Grade C).
PCC is not recommended in patients with ICH
under dabigatran therapy (Grade C).
In NOAC–ICH, serial plasma concentration mea-
surement is recommended to account for potential
rebound effects (Grade C).
Q2: In AIS, how is optimal reversal under VKA or
NOAC achieved to minimize bleeding complications with
revascularization therapies?
Recommendations: Patients with AIS under VKA or
NOAC treatment with proven large vessel occlusion
should be offered IVT (if feasible) and endovascular
treatment (thrombectomy) (Grade C).
In AIS under VKA treatment and otherwise eligible
for thrombolysis:
• In INR  1.7: IVT (alteplase) should be adminis-
tered (Grade C).
• In INR> 1.7: The current evidence does not support
a statement in favour for or against IVT after rever-
sal with PCC (Grade C).
In AIS under NOAC treatment and otherwise eligible
for thrombolysis:
• Relevant drug concentrations in patients on NOACs
must be assumed if
• Global routine tests (activated partial thrombo-
plastin time [aPTT] and/or prothrombin time
(PT)/INR) are above normal (Grade C).
• If calibrated agent-specific tests or the Ecarin clot-
ting time (dabigatran only) indicate concentra-
tions >30 ng/mL.
• Global routine tests (aPTTandPT/INR)withinnormal
ranges do not exclude relevant drug concentrations and
should not be used to guide therapy (Grade C).
• In case of dabigatran, administration of idarucizu-
mab (Bolus 2 2.5 g intravenously) followed by IVT
might be considered even without specific laboratory
tests (Grade C).
• In case of factor Xa inhibitors, IVT might be con-
sidered without prior reversal if calibrated agent-
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specific tests indicate NOAC concentration <30 ng/
mL (Grade C).
• Point-of-care testing may accelerate IVT. The fol-
lowing thresholds indicating NOAC plasma levels
<30 ng/mL allowing for IVT are currently available
for the HemochronVR Signature Elite device only
(Grade C).
• Dabigatran HemochronVR Signature Elite-PT/INR
1.1 or HemochronVR Signature Elite-ACTþ
100 s.
• Edoxaban HemochronVR Signature Elite-PT/
INR 1.4.
• Rivaroxaban HemochronVR Signature Elite-PT/
INR 1.0 or HemochronVR Signature Elite-
ACTþ 120 s.
• For Apixaban, currently no reliable tests
are available.
Q3: In patients after acute ICH with the indication for
oral anticoagulation, does (re)initiation of oral anticoag-
ulant therapy compared to no therapy or compared to
antiplatelet therapy, improve outcomes (mortality, func-
tional outcome, and rates of thromboembolic/haemor-
rhagic complications)?
Recommendation: Enrolment in randomised con-
trolled trials investigating the optimal antithrombotic
management after ICH is strongly recommended.
In selected ICH patients, (re)initiation of OAC com-
pared to no OAC may improve outcomes without
increasing the rate of ICH recurrence (Grade C).
NOAC over VKA may offer a safer choice for ICH
survivors with NVAF (Grade C).
Re-initiation of OAC in NVAF between the first
four to eight weeks from index ICH seems to be safe
(Grade C).
Individual decision making on OAC after ICH
should consider (Grade C): quality of BP control,
age, ICH location, burden of small vessel disease (cere-
bral microbleeds (CMBs), leukoaraiosis, cortical super-
ficial siderosis, CAA), additional antiplatelet therapy.
Q4: In patients after a CAA-related lobar ICH with
concomitant indication for oral anticoagulation due to
non-valvular AF, how is optimal antithrombotic manage-
ment achieved to improve outcomes (mortality, function-
al outcome and rates of thromboembolic/haemorrhagic
complications)?
Recommendation: In patients with CAA-related
lobar ICH in need of OAC:
• The presence of AF might confer enough risk for
ischaemic stroke, poor outcomes and mortality to
offset the presumed risk of ICH recurrence in select-
ed patients (Grade C).
• The following parameters can be considered for an
individual risk versus benefit stratification, in order
of significance based on observational data: uncon-
trolled hypertension, disseminated Cortical superfi-
cial siderosis (cSS), multiple strictly lobar CMB
patterns, severe white matter hyperintensities of pre-
sumed vascular origin (Grade C).
• NOACs should preferentially be used over VKA in
NVAF (Grade C).
• In NVAF patients with high bleeding risk LAAO
may be an alternative (Grade C).
Q5: In patients after AIS with CMBs on MRI and the
concomitant indication for oral anticoagulation due to
AF, how is optimal antithrombotic management achieved
to improve outcomes (mortality, functional outcome, and
rates of thromboembolic/haemorrhagic complications)?
Recommendation: In patients with ischaemic stroke
and need of OAC:
• OAC in patients with evidence of CMBs should not
be withheld (Grade C).
• NOACs should preferentially be used over VKA in
NVAF (Grade C).
Session 10: IVT in AIS
Chair: G€otz Thomalla (Hamburg) and Robert Mikulik
(Brno). Secretary: Michael Mazya (Stockholm).
Speakers: Pooja Khatri (Cincinnati), William
Whiteley (Edinburg), G€otz Thomalla (Hamburg),
Eivind Berge (Oslo).
Q1: Should patients with minor stroke be treated with
intravenous thrombolysis?
Consensus statement:
1. For patients with minor stroke considered dis-
abling at assessment, treatment with intravenous alte-
plase can be considered (Grade A).
2. For patients with minor stroke considered non-
disabling at assessment, routine treatment with intra-
venous alteplase is not recommended (Grade B). In
cases considered to be at high risk of neurological dete-
rioration, treatment with intravenous thrombolysis can
be considered (Grade C).
Q2: Should patients with known symptom onset
beyond 4.5 h be treated with intravenous thrombolysis?
Consensus statement: 1. For patients with AIS 4.5–9
h from symptom onset with a ‘penumbral mismatch’
identified by MRI or CT perfusion, intravenous alte-
plase may be considered (Grade C). Randomized trial
results are expected shortly and may result in a strength-
ened recommendation at a higher grade of evidence.
2. For patients with AIS beyond 4.5 h from symptom
onset, but with no evidence of penumbral mismatch
(e.g. patients selected by non-contrast CT only),
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intravenous alteplase is not recommended
(Grade A).
Q3: Should patients with unknown onset stroke be
treated with intravenous thrombolysis?
Consensus statement:
1. Intravenous alteplase is recommended in patients
with AIS with an unknown onset time in the presence
of a DWI (Diffusion weighted imaging)–FLAIR
(Fluid-attenuated inversion recovery) mismatch on
acute MRI (i.e. the mismatch between the visibility of
an acute ischaemic lesion on DWI in the absence of a
visible marked parenchymal hyperintensity on FLAIR
in the corresponding area) (Grade B).
2. For patients with AIS with an unknown onset
time with presence of a ‘penumbral mismatch’ on
MRI or CT perfusion, intravenous alteplase may be
considered (Grade C). Randomized trial results are
expected shortly and may result in a strengthened rec-
ommendation at a higher grade of evidence.
3. For patients without access to advanced imaging
(MRI or CT perfusion), or those without DWI–
FLAIR mismatch and without penumbral mismatch,
alteplase is not recommended (Grade C) and enrolment
into randomised controlled trials is encouraged.
Q4: Should tenecteplase be used for intravenous
thrombolysis instead of alteplase?
Consensus statement: Tenecteplase instead of alte-
plase is not recommended for treatment of patients
with AIS in routine practice (Grade C).
Session 11: Mechanical thrombectomy
Chair: Gary A. Ford (Oxford) and Joan Marti-
Fabregas (Barcelona). Secretary: A˚sa Kuntze
S€oderqvist (Stockholm). Speakers: Diederik W.J.
Dippel (Roterdam), Gary A. Ford (Oxford), Satu
Mustanoja (Helsinki), Mads Rasmussen (Aarhus).
Q1: In patients with AIS presenting with large vessel
occlusion and possible to administer iv thrombolytics
within 4.5 hours where thrombectomy is planned,
should iv thrombolytics be administered?
Consensus statement: Patients with AIS should be
treated with IV alteplase without delay if there are no
contra-indications. Subsequent transportation to an
intervention centre if a proximal intracranial arterial
occlusion is considered present should follow urgently
(drip and ship). As long as there is no direct evidence of
superiority, or at least non-inferiority of thrombectomy
without preceding IV alteplase in patients who are eli-
gible for both treatments, we advise that patients who
present directly at an intervention centre should be
treated with IV alteplase as indicated and thrombec-
tomy should follow as soon as possible.
Recommendation: Patients with AIS should be
treated with IV alteplase without delay if there are no
contra-indications. In case of a proximal intracranial
thromboembolic occlusion causing the ischaemic
stroke, thrombectomy should follow as soon as possi-
ble after starting thrombolysis (Grade C).
The effect of immediate thrombectomy, bypassing
treatment with IV thrombolysis needs to be addressed
in specifically designed randomised trials (not graded).
Q2: Which patients presenting beyond 6 hours or with
unwitnessed stroke does thrombectomy improve the like-
lihood of a good outcome?
Q3: What imaging is recommended to select patients
presenting beyond 6 h or with unwitnessed stroke for
thrombectomy?
Consensus statement: According to the study results
from DAWN and DEFUSE-3 trials, the efficacy of
thrombectomy in carefully selected patients with
Large vessel occlusion (LVO) in the anterior circulation
up to 24 h after suspected stroke symptom onset can be
considered to be safe and efficient. The use of collateral
imaging to select patients presenting beyond 6 h for
Endovascular thrombectomy (EVT) appears promising
but further data are needed before this can be recom-
mended for routine use in selecting patients for EVT in
the later time window. Detection of LVO in the new
treatment window demands (sufficient organization of
services to ensure) rapid transfer of more (eligible)
patients to centres providing EVT, with immediate
access to multi-modal advanced imaging and its inter-
pretation, and a well-trained multidisciplinary work-
force to deliver specialist pre-, peri-, and post-
thrombectomy care.
Recommendation: For patients presenting 6–24
h after onset with ICA or M1 occlusion with a dis-
abling deficit National Institutes of Health Stroke
Scale (NIHSS)> 6 and no significant pre-stroke dis-
ability, selection for thrombectomy can be guided by
utilizing perfusion imaging to identify patients with an
imaging profile treated in the DAWN/DEFUSE trials
(Grade A).
Q4: In patients undergoing endovascular procedures
should conscious sedation or general anaesthesia be used?
Consensus statement: Until further data are avail-
able, General anaesthesia (GA) and Conscious seda-
tion (CS) can equally be considered for EVT
procedural sedation. It is suggested that the specific
choice of anesthetic technique during EVT for LVO
is individualized and based on clinical neurological pre-
sentation (especially involuntary movements), co-
morbidity and current medical condition (airway, vom-
iting). Management of anaesthesia for EVT is prefera-
bly performed by a dedicated anaesthesia team in order
to rigorously maintain BP (systolic BP >140 mmHg)
(7) and minimize time delay.
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Recommendation: We recommend an anaesthetist is
present during EVT (Grade C).
No preference for general anaesthesia and conscious
sedation/local anaesthesia can be recommended when
there is no indication for general anaesthesia (Grade C).
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